Ozempic & GLP-1 Gastroparesis Lawsuit 2026: MDL 3094 Eligibility, Process, Fees

GLP-1 gastroparesis lawsuits: the essentials first

Let me be blunt. This is not a lawsuit saying GLP-1 drugs failed to help people lose weight. It is a failure-to-warn fight: people who used Ozempic, Wegovy, Mounjaro or Zepbound and then suffered gastroparesis (severely delayed stomach emptying) or bowel obstruction argue that manufacturers did not adequately warn about that risk on the U.S. label.

Two things up front. First, as of 2026 there is no finalized settlement. MDL 3094 is still fighting over general causation and working through discovery. Ads promising “you’ll get $X for taking a GLP-1” have no basis. Second, eligibility is decided by records — proof of use and a diagnosis — not by the reason you took the drug.

GLP-1 prescriptions exploded over the past few years. As volume surged, so did reports that the drugs’ known slowing of stomach emptying tipped some patients into serious GI problems. That is the seed of this litigation. If you want to see how regulatory and litigation risk gets absorbed into drug-supply-chain companies, an analysis like West Pharmaceutical stock outlook is a useful reference point.

What the claim is built on

GLP-1 receptor agonists boost insulin and slow gastric emptying to increase satiety. That delayed emptying is part of how the drugs work. The problem, plaintiffs argue, is that in some patients it worsened into chronic gastroparesis, recurrent vomiting, and in severe cases bowel obstruction.

The plaintiffs’ theory:

• Manufacturers could have known that GLP-1s’ gastric-slowing action carried a risk of serious GI injury.
• The U.S. label nonetheless failed to reflect the severity and frequency adequately.
• Patients and doctors were thereby limited in their ability to weigh the risk.

A pivotal early issue is general causation — whether GLP-1s can, as a scientific matter, actually cause gastroparesis. That fight is the make-or-break checkpoint early in the MDL and heavily shapes where everything else goes.

Do I qualify?

The ad is simple; the real screen is specific.

Factor	Helps	Works against
Drug	Documented Ozempic/Wegovy/Mounjaro/Zepbound use	Drug used unclear
Injury	Diagnosed gastroparesis / bowel obstruction	Transient nausea only
Timing	Onset after use	Pre-existing GI disease
Records	Prescription and diagnosis records obtainable	Records lost
Deadline	Diagnosis relatively recent	Old diagnosis, limitations expired

Important caveat: the transient nausea and indigestion most GLP-1 users experience are not the basis for this litigation. What matters is a diagnosed, serious GI injury, plus provable causation and damages. Whether a contingency firm takes your case is effectively the first eligibility screen.

Process and timeline

Stage	What happens	Rough duration
Screening	Free consult, records review, intake	Days to weeks
Filing / MDL 3094 transfer	Individual complaint filed and consolidated	Weeks to months
General-causation fight	Scientific evidence and expert battles	A year-plus
Bellwether trials	Sample cases tried to gauge juries	Years
Settlement or individual trials	Negotiation or separate trials	Varies

Large pharmaceutical MDLs tend to resolve through negotiated settlements eventually, but the timing is unpredictable and often runs years. Joining now does not mean money soon — understand that horizon before you sign.

Fees and costs

• Contingency rates are typically 33% to 40% of the recovery.
• Litigation costs (expert fees, records) are usually reimbursed separately.
• Take-home = award − fee − costs.

Before signing, confirm the fee percentage and whether it is calculated before or after costs, who owes costs if the case loses, and who holds settlement authority. For a view of how liability risk is priced on the back end, Chubb insurance stock outlook shows how insurers quantify the exposure that funds many settlements.

Common mistakes

• Believing dollar promises — no settlement is finalized.
• Expecting a case from mild symptoms — undiagnosed nausea does not qualify.
• Signing with multiple firms — one claim, one retainer.
• Sitting on the deadline — the statute of limitations can end the claim.

Anyone impersonating a court or agency to demand a “participation fee” is running a scam. Legitimate contingency firms never charge upfront.

A self-check before you commit

• Actually used a GLP-1 (Ozempic/Wegovy/Mounjaro/Zepbound)
• Diagnosed and treated for gastroparesis or serious GI injury
• Able to obtain use and diagnosis records
• Statute of limitations still open from the diagnosis date
• Understood the fee and cost terms in writing

If all five are “yes,” a sensible step is a free consultation with two or three firms actually handling MDL 3094 before deciding. To see how drug-development risk and reward play out on the equity side, an analysis like Madrigal Pharmaceuticals stock outlook is a useful companion read.

Bottom line

The Ozempic gastroparesis litigation (MDL 3094) is ongoing, and much of the outcome still hinges on the general-causation fight. Whether you should join comes down to whether your use and diagnosis records meet the bar and whether you can outlast a multi-year process. To get ahead on the tax side of any eventual recovery, the process-first capital gains tax filing guide is worth reading alongside this.

Related reading

These posts cover adjacent ground.

• 👉 Mdlz Mondelez
• 👉 Gc Biopharma 006280

---

This article is general information, not legal, tax, or insurance advice. Consult a licensed professional about your specific situation.